Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Lurbinectedin by Jazz Pharmaceuticals for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Lurbinectedin is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...
Lurbinectedin by Jazz Pharmaceuticals for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Lurbinectedin is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Human Epidermal Growth Factor Receptor 2...
Lurbinectedin by Jazz Pharmaceuticals for Esophageal Cancer: Likelihood of Approval
Lurbinectedin is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase...
Zanidatamab by Jazz Pharmaceuticals for Metastatic Biliary Tract Cancer: Likelihood of Approval
Zanidatamab is under clinical development by Jazz Pharmaceuticals and currently in Pre-Registration for Metastatic Biliary Tract Cancer. According to GlobalData,...
Zanidatamab by Jazz Pharmaceuticals for Extrahepatic Bile Duct Cancer: Likelihood of Approval
Zanidatamab is under clinical development by Jazz Pharmaceuticals and currently in Phase III for Extrahepatic Bile Duct Cancer. According to...
Zanidatamab by Jazz Pharmaceuticals for Gallbladder Cancer: Likelihood of Approval
Zanidatamab is under clinical development by Jazz Pharmaceuticals and currently in Phase III for Gallbladder Cancer. According to GlobalData, Phase...
Zanidatamab by Jazz Pharmaceuticals for Bladder Cancer: Likelihood of Approval
Zanidatamab is under clinical development by Jazz Pharmaceuticals and currently in Phase I for Bladder Cancer. According to GlobalData, Phase...
Zanidatamab by Jazz Pharmaceuticals for Pancreatic Cancer: Likelihood of Approval
Zanidatamab is under clinical development by Jazz Pharmaceuticals and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase...
Lurbinectedin by Jazz Pharmaceuticals for Neuroendocrine Carcinoma: Likelihood of Approval
Lurbinectedin is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Neuroendocrine Carcinoma. According to GlobalData, Phase...
Zanidatamab by Jazz Pharmaceuticals for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Zanidatamab is under clinical development by Jazz Pharmaceuticals and currently in Phase III for Adenocarcinoma Of The Gastroesophageal Junction. According...
Defibrotide sodium by Jazz Pharmaceuticals for Sickle Cell Disease: Likelihood of Approval
Defibrotide sodium is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Sickle Cell Disease. According to...
Lurbinectedin by Jazz Pharmaceuticals for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval
Lurbinectedin is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer. According...
Lurbinectedin by Jazz Pharmaceuticals for Metastatic Biliary Tract Cancer: Likelihood of Approval
Lurbinectedin is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Metastatic Biliary Tract Cancer. According to...
Cannabidiol by Jazz Pharmaceuticals for Infantile Spasm (West Syndrome): Likelihood of Approval
Cannabidiol is under clinical development by Jazz Pharmaceuticals and currently in Phase III for Infantile Spasm (West Syndrome). According to...
Defibrotide sodium by Jazz Pharmaceuticals for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome: Likelihood of Approval
Defibrotide sodium is under clinical development by Jazz Pharmaceuticals and currently in Phase I for Coronavirus Disease 2019 (COVID-19) Associated...
Zanidatamab by Jazz Pharmaceuticals for Breast Cancer: Likelihood of Approval
Zanidatamab is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Breast Cancer. According to GlobalData, Phase...
Lurbinectedin by Jazz Pharmaceuticals for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval
Lurbinectedin is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer. According...
Lurbinectedin by Jazz Pharmaceuticals for Metastatic Biliary Tract Cancer: Likelihood of Approval
Lurbinectedin is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Metastatic Biliary Tract Cancer. According to...
Risk adjusted net present value: What is the current valuation of Jazz Pharmaceuticals's JZP-898?
JZP-898 is a fusion protein commercialized by Jazz Pharmaceuticals, with a leading Phase I program in Metastatic Transitional (Urothelial) Tract...
Risk adjusted net present value: What is the current valuation of Jazz Pharmaceuticals's Zanidatamab?
Zanidatamab is a monoclonal antibody commercialized by Jazz Pharmaceuticals, with a leading Pre-Registration program in Metastatic Biliary Tract Cancer. According...